I'm LongbridgeAI, I can summarize articles.XLV.US fell 2.65% this week to close at $166.18, trailing the S&P 500’s -0.27% by roughly 2.38 percentage points. The ETF opened Monday at $169.97 and touched a weekly high of $171.87 before turning lower. Tuesday held near $170.73, but the final three sessions saw consecutive declines, with Friday trading as low as $165.27 before settling at $166.18. The weekly range was 3.88%, leaving a pattern of an early push higher followed by a pullback and a quiet finish.
The Week
XLV.US fell 2.65% this week to close at $166.18, trailing the S&P 500’s -0.27% by roughly 2.38 percentage points. The ETF opened Monday at $169.97 and touched a weekly high of $171.87 before turning lower. Tuesday held near $170.73, but the final three sessions saw consecutive declines, with Friday trading as low as $165.27 before settling at $166.18. The weekly range was 3.88%, leaving a pattern of an early push higher followed by a pullback and a quiet finish.
Sector News
Healthcare news this week was dominated by clinical data, deal activity, and Medicare policy. Eli Lilly (LLY) released a series of obesity-related updates, with Retatrutide showing weight loss over eighty weeks and once-daily oral Orforglipron linked to reduced heart disease risk. AbbVie (ABBV) reported positive data across atopic dermatitis and obesity candidates, while Rinvoq’s Phase 3 vitiligo repigmentation gains extended to week 76. Merck (MRK) committed $2.13 billion to a KRAS inhibitor and said tulisokibart met the primary endpoint in a Phase 2b hidradenitis suppurativa trial. On policy, CMS projected Medicare Advantage premiums will drop more than 16% in 2027, and UnitedHealth pushed $0 premium options. The sector saw heavy data flow from large-cap pharma, but its relation to the index’s milder move this week should be read as correlation rather than cause.
The Week Ahead
On the macro calendar, Monday brings the final US S&P Global services PMI and ISM non-manufacturing PMI, with the former at a prior 58.7 and the latter at 55.4 prior versus a 55 forecast. Tuesday features international trade data with a prior of -$88.6 and a forecast of -$102, and Wednesday has the weekly EIA crude oil and Cushing inventories. Within healthcare, third-quarter earnings for Johnson & Johnson and Abbott are approaching, while the market digests follow-up details from this week’s concentrated clinical releases from Lilly, AbbVie, and Merck. No specific healthcare earnings dates are listed in the calendar yet, but services data and Medicare policy developments next week could shape broader sector sentiment.
In Short
XLV.US dropped 2.65% this week despite heavy positive clinical headlines across healthcare, while the S&P 500 eased only 0.27%. Valuation shows a PE of 16.69x and PB of 1.29x, which is not stretched. The latest trading day’s flow data shows large and medium orders net selling, while small orders were net buyers, and broker ratings remain generally constructive: Scotiabank initiated AbbVie at buy, Rothschild upgraded Abbott to buy, and RBC kept buy ratings on Abbott and Lilly. The gap between sector news and index performance, the split in money flows, and the firm ratings backdrop create a mixed tension. What matters next is how the services data and Medicare policy shape macro expectations, and whether follow-through from the big pharma data widens divergence within the sector.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.